ClinicalTrials.gg
CompletedNCT00687804RESTOREUpdated Apr 1, 2013Results posted

A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study

A Phase 3 interventional study of Ranibizumab and Laser in Diabetic Macular Edema, sponsored by Novartis. Completed at 13 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-01.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing ranibizumab in Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Edema.

Enrollment
4th of 13
345 · median 50
Started
2008
with 1 other
Phase 3
5 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
2 of 13
Novartis

Among the 13 studies testing ranibizumab in Edema, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 5 in phase 3, and was the 4th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

None of the 13 studies testing ranibizumab in Edema is open now. The open studies under Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ranibizumab in Edema as a file.
02

Study summary

CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.

CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Diabetic
  • macula
  • edema
  • ranibizumab
  • RESTORE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual acuity impairment
  • Diabetic macular edema in at least one eye
  • Type 1 or type 2 diabetes mellitus
  • Medication for the diabetes treatment must be stable for the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled systemic or ocular diseases
  • Laser photocoagulation in the study eye for the last 3 months
  • Any history of any intraocular surgery in the study eye within the past 3 months
  • Blood pressure > 160/100 mmHg

Extension Inclusion Criteria:

-Completion of the Core Study

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.

    Drug: Ranibizumab · Procedure: Laser · Procedure: Sham laser

  • Experimental
    Ranibizumab 0.5 mg + laser

    Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.

    Drug: Ranibizumab · Procedure: Laser

  • Active comparator
    Laser

    Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.

    Drug: Ranibizumab · Procedure: Laser · Drug: Sham to ranibizumab

Interventions

  • 0.5 mg ranibizumab administered by intravitreal injection.

  • ProcedureLaser

    Laser photocoagulation treatment

  • ProcedureSham laser

    Sham to laser procedure.

  • DrugSham to ranibizumab

    Sham to ranibizumab administered as an intravitreal injection.

06

What researchers measure

Primary outcomes

  1. Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Baseline through the end of study (Month 12)

  2. Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study

    Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

    Time frame: Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]

  3. Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study

    Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

    Time frame: Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]

Secondary outcomes

  1. Core Study: Categorized Change in Visual Acuity (Letters) of the Study Eye From Baseline at Month 12

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Baseline to Month 12

  2. Core Study: Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

    Time frame: Baseline to Month 12

  3. Core Study: Mean Change From Baseline at Month 12 in Central Retinal Thickness of the Study Eye

    Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation.

    Time frame: Baseline to Month 12

  4. Core Study: Mean Change From Baseline in Patient-reported Visual Functioning

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

    Time frame: Baseline to Month 12

  5. Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 36 Months of the Core and Extension Studies

    Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

    Time frame: Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 months]

  6. Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 36 Months of the Core and Extension Studies

    Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about Adverse Events can be found in the Adverse Event section.

    Time frame: Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 Months]

  7. Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.

    Time frame: Extension baseline (Month12 -end of core study), Month 36 (end of extension study)

  8. Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.

    Time frame: Core baseline (Day 1 of the core study), Month 36 (end of extension study)

07

Results

Posted Apr 19, 2011

Participant flow

Core Study
Participant flow — Core Study
MilestoneRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Started116118111
Completed10210398
Not completed141513
Withdrew: Adverse event533
Withdrew: Abnormal laboratory value(s)100
Withdrew: Lack of efficacy111
Withdrew: Withdrawal by subject477
Withdrew: Lost to follow-up010
Withdrew: Death222
Withdrew: Protocol violation110
Open-Label Extension Study
Participant flow — Open-Label Extension Study
MilestoneRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Started838374
Did not receive ranibizumab in extension162115
Completed737263
Not completed101111
Withdrew: Adverse event222
Withdrew: Subject withdrew consent344
Withdrew: Lost to follow-up212
Withdrew: Administrative problems110
Withdrew: Death233

Outcome measures

PrimaryCore Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Baseline through the end of study (Month 12)
Reported as:
Mean · Letters
Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12
LettersRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Baseline64.7 ± 10.0763.4 ± 9.9962.6 ± 11.01
Average Month 1 to month 1270.8 ± 10.5369.2 ± 11.4463.4 ± 12.26
Change from Baseline6.1 ± 6.435.9 ± 7.920.8 ± 8.56
SecondaryCore Study: Categorized Change in Visual Acuity (Letters) of the Study Eye From Baseline at Month 12

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Baseline to Month 12
Reported as:
Number · Participants
Core Study: Categorized Change in Visual Acuity (Letters) of the Study Eye From Baseline at Month 12
ParticipantsRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Gain of ≥ 10 letters435117
Loss of ≥ 10 letters4514
Gain of ≥ 15 letters26279
Loss of ≥ 15 letters149
SecondaryCore Study: Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.

Time frame:
Baseline to Month 12
Reported as:
Mean · Letters
Core Study: Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time
LettersRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Month 12.9 ± 0.493.1 ± 0.560.5 ± 0.64
Month 24.4 ± 0.644.9 ± 0.560.4 ± 0.84
Month 35.9 ± 0.655.8 ± 0.65-0.5 ± 0.92
Month 45.3 ± 0.685.4 ± 0.690.5 ± 0.92
Month 55.9 ± 0.685.7 ± 0.760.9 ± 0.88
Month 66.7 ± 0.686.2 ± 0.780.9 ± 0.94
Month 77.0 ± 0.726.5 ± 0.841.1 ± 0.98
Month 87.1 ± 0.756.4 ± 1.061.3 ± 0.96
Month 96.8 ± 0.766.8 ± 1.051.4 ± 0.90
Month 107.3 ± 0.776.4 ± 1.040.8 ± 1.00
Month 116.9 ± 0.796.8 ± 1.101.4 ± 0.95
Month 126.8 ± 0.776.4 ± 1.080.9 ± 1.09
SecondaryCore Study: Mean Change From Baseline at Month 12 in Central Retinal Thickness of the Study Eye

Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation.

Time frame:
Baseline to Month 12
Reported as:
Mean · Micrometers
Core Study: Mean Change From Baseline at Month 12 in Central Retinal Thickness of the Study Eye
MicrometersRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Baseline427.1 ± 118.42416.4 ± 119.91412.4 ± 124.53
Value at Month 12308.4 ± 112.26288.2 ± 90.11351.1 ± 139.91
Change from Baseline-118.7 ± 115.07-128.3 ± 114.34-61.3 ± 132.29
SecondaryCore Study: Mean Change From Baseline in Patient-reported Visual Functioning

The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.

Time frame:
Baseline to Month 12
Reported as:
Mean · Units on a scale
Core Study: Mean Change From Baseline in Patient-reported Visual Functioning
Units on a scaleRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser
Baseline72.8 ± 16.9174.1 ± 18.0673.5 ± 18.18
Month 1277.8 ± 19.1979.5 ± 17.2974.1 ± 18.80
Change from Baseline5.0 ± 12.975.4 ± 11.140.6 ± 12.56
PrimaryExtension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study

Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

Time frame:
Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Reported as:
Number · Percentage of participants
Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study
Percentage of participantsRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
Adverse Events56.656.652.540.0
Serious Adverse Events2.41.21.70.0
SecondaryExtension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 36 Months of the Core and Extension Studies

Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

Time frame:
Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 months]
Reported as:
Number · Percentage of participants
Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 36 Months of the Core and Extension Studies
Percentage of participantsRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
Adverse Events66.367.564.446.7
Serious Adverse Events2.43.65.10.0
SecondaryExtension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 36 Months of the Core and Extension Studies

Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about Adverse Events can be found in the Adverse Event section.

Time frame:
Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 Months]
Reported as:
Number · Percentage of participants
Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 36 Months of the Core and Extension Studies
Percentage of participantsRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
Adverse Events83.181.984.773.3
Serious Adverse Events36.137.342.413.3
PrimaryExtension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study

Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.

Time frame:
Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Reported as:
Number · Percentage of participants
Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study
Percentage of participantsRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
Adverse Events73.573.571.273.3
Serious Adverse Events27.730.137.313.3
SecondaryExtension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.

Time frame:
Extension baseline (Month12 -end of core study), Month 36 (end of extension study)
Reported as:
Mean · Letters
Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36
LettersRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserActive Laser
Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 360.1 ± 9.10-0.5 ± 9.193.7 ± 6.88
SecondaryExtension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.

Time frame:
Core baseline (Day 1 of the core study), Month 36 (end of extension study)
Reported as:
Mean · Letters
Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36
LettersRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserActive Laser
Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 368.0 ± 10.096.7 ± 9.596.0 ± 9.35

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg—41/115 (35.7%)79/115 (68.7%)
Ranibizumab 0.5 mg + Laser—43/120 (35.8%)83/120 (69.2%)
Laser With Ranibizumab in Extension—28/59 (47.5%)50/59 (84.7%)
Laser Without Ranibizumab in Extension—7/51 (13.7%)31/51 (60.8%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
Cardiac failureCardiac disorders1/1151/1204/591/51
Myocardial infarctionCardiac disorders1/1154/1203/590/51
PneumoniaInfections and infestations0/1151/1203/590/51
Diabetic footMetabolism and nutrition disorders2/1150/1203/591/51
Acute myocardial infarctionCardiac disorders1/1150/1202/590/51
Cataract (Study eye)Eye disorders0/1153/1202/590/51
Angina pectorisCardiac disorders3/1151/1200/590/51
Coronary artery diseaseCardiac disorders3/1151/1201/590/51
FallInjury, poisoning and procedural complications3/1150/1200/590/51
Cerebrovascular accidentNervous system disorders3/1151/1201/590/51
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRanibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaser With Ranibizumab in ExtensionLaser Without Ranibizumab in Extension
NasopharyngitisInfections and infestations18/11521/12015/598/51
Eye pain (Study eye)Eye disorders15/11511/12013/592/51
Diabetic retinal oedema (Fellow eye)Eye disorders12/11519/12011/593/51
Cataract (Study eye)Eye disorders9/11517/1209/594/51
InfluenzaInfections and infestations12/1158/1208/595/51
Back painMusculoskeletal and connective tissue disorders7/1155/1208/591/51
HypertensionVascular disorders15/11511/1206/596/51
Cataract (Fellow eye)Eye disorders10/11512/1207/595/51
Conjunctival haemorrhage (Study eye)Eye disorders9/11513/1200/590/51
Conjunctival hyperaemia (Study eye)Eye disorders9/1158/1205/592/51

Baseline characteristics

Age Continuous
Age Continuous(years)Ranibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaserTotal
Mean62.9 ± 9.2964.0 ± 8.1563.5 ± 8.8163.5 ± 8.75
Age, Customized
Age, Customized(Participants)Ranibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaserTotal
< 55 years24141351
55 - <65 years414253136
65 - <75 years405331124
>=75 years1191434
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mgRanibizumab 0.5 mg + LaserLaserTotal
Female434853144
Male737058201
08

Study locations

13 sites
  • Novartis Investigative Site
    Melbourne, Australia
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Ontario, Canada
  • Novartis Investigative Site
    Paris, France
  • Novartis Investigative Site
    Düsseldorf, Germany
  • Novartis Investigative Site
    Athens, Greece
  • Novartis Investigative Site
    Budapest, Hungary
  • Novartis Investigative Site
    Firenze, Italy
  • Novartis Investigative Site
    Amsterdam, Netherlands
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigational Site
    Zurich, Switzerland
  • Novartis Investigative Site
    Ankara, Turkey
  • Novartis Investigative Site
    Upton, United Kingdom
09

References and documents

Publications

  • Bressler NM, Varma R, Mitchell P, Suner IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials. JAMA Ophthalmol. 2016 Feb;134(2):160-6. doi: 10.1001/jamaophthalmol.2015.4636. PubMed 26584450 ↗
  • Mitchell P, Massin P, Bressler S, Coon CD, Petrillo J, Ferreira A, Bressler NM. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study. Curr Med Res Opin. 2015 Nov;31(11):1967-75. doi: 10.1185/03007995.2015.1081880. Epub 2015 Oct 6. PubMed 26327116 ↗
  • Bressler NM, Varma R, Suner IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A; RIDE and RISE Research Groups. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology. 2014 Dec;121(12):2461-72. doi: 10.1016/j.ophtha.2014.07.008. Epub 2014 Aug 20. PubMed 25148789 ↗
  • Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F; RESTORE Study Group. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol. 2013 Oct;131(10):1339-47. doi: 10.1001/jamaophthalmol.2013.4592. PubMed 23974915 ↗
  • Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031. PubMed 21459215 ↗
  • Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014 May;121(5):1045-53. doi: 10.1016/j.ophtha.2013.11.041. Epub 2014 Feb 1. PubMed 24491642 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jan 2010 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
Jun 2, 2008
Start
May 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2012
Results first posted
Apr 19, 2011
Last update
Apr 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00687804
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jun 2, 2008
Start date
May 2008
Primary completion
Jan 2010
Completion
Jan 2012
Results posted
Apr 19, 2011
Last update
Apr 1, 2013

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion